Germ cell tumours (GCT) are the most common malignancies in young men aged between 15 and 35 years. 1 Options for the treatment of patients with primary resistant or relapsed disease include second-line regimens of conventional-dose chemotherapy (CDCT) combining cisplatin and ifosfamide with either vinblastine 2 or paclitaxel 3 or, alternatively, high-dose chemotherapy (HDCT) with autologous stem cell support (autoSCT). 4, 5 In the absence of conclusive evidence from clinical trials, the precise indications for the use of HDCT and autoSCT remain unclear.
Since 1993, the Memorial Sloan-Kettering Cancer Center (MSKCC) has been using the TI-CE (two cycles of taxol (paclitaxel)/ifosfamide (TI) followed by three cycles of high-dose carboplatin and etoposide (CE)) regimen in previously treated GCT patients who have the following unfavourable prognostic features: (1) extra-gonadal primary site (primary tumour outside testes), (2) primary platinum-refractory disease (progression within four weeks of initial chemotherapy) or progression following an incomplete response (IR) to first-line therapy (remission less than six months) and (3) relapse/IR following first attempted salvage with CDCT. [6] [7] [8] We have been using this regimen at the National Adult SCT centre at St. James's Hospital in Dublin since 1998. The MSKCC criteria were applied prospectively at the time of relapse. Patients with brain metastases as the site of first relapse, however, were excluded. We here report a 17-year retrospective review of our experience in 30 patients.
Hospital records were reviewed and baseline, transplant, response and survival data collected. Survival data was censored as of 30 June 2015.
Salvage chemotherapy consisted of paclitaxel (200 mg/m 2 /day on day 1) and ifosfamide (2000 mg/m 2 /day on days 2-4) for two cycles 14 days apart. Stem cell collection was performed on cell count recovery. The target stem cell dose was 7.5 × 10 6 CD34+ cells per kg recipient body weight.
Carboplatin was dosed according to a target area under curve (AUC) and administered with etoposide at a dose of 400 mg/m 2 /day IV on days − 6, − 5 and − 4 of cycles 3-5 (total dose per cycle, 1200 mg/m 2 ). The target AUC was 21 in three divided doses for patients who had received two prior CDCT regimens and 24 for those who had only received first-line therapy. The cryopreserved autologous stem cell products were thawed and infused IV on day 0. G-CSF 5 μg/kg was commenced on day +5 and continued until engraftment. Autologous stem cell support was planned to be given at three weekly cycles.
All patients had cross-sectional imaging performed post-transplant and those with evidence of residual tumour were considered for surgical resection, if technically feasible. There were three categories of response: (1) CR applied to patients with no clinical, radiological or biochemical (that is, tumour marker) evidence of disease post-HDCT and included patients who underwent post-HDCT surgery and in whom no viable tumour was found; (2) CR post-surgery (CRPS) referred to patients with no evidence of disease after surgical resection of viable disease; (3) IR applied to patients who failed to achieve a durable CR after HDCT +/ − surgery.
PFS and overall survival (OS) were estimated using the KaplanMeier method.
Between January 1998 and August 2014, a total of 30 patients with histologically proven advanced metastatic GCT were treated with the TI-CE regimen. TI was administered as an inpatient and leucapheresis performed as an outpatient. For the transplant admissions, patients were admitted on the day prior to conditioning and remained in hospital until engraftment.
All patients had received at least three cisplatin-based treatment cycles and failed to achieve a durable CR. Twenty-two patients had received at least three cycles of concomitant bleomycin. Progressive disease was documented by rising markers and/or radiological progression.
Judged against the eligibility criteria for the MSKCC trial, at least one unfavourable prognostic feature for successful salvage with CDCT was present in all but one case, the exception being a patient who had relapsed seven months after initial cisplatinbased chemotherapy.
The International Prognostic Factors Study Group (IPFSG) score was calculated for the 24 patients who were treated with TI-CE as first salvage. 9 Baseline patient characteristics are shown in Table 1a .
Twenty-eight (93%) of the 30 patients received two cycles of TI and underwent stem cell collection following the first and/or second cycle. One patient completed a third cycle of TI to ensure an adequate stem cell collection and another received only one cycle of TI given prior paclitaxel-related neuropathy. Twenty-three (77%) patients reached the target stem cell dose within one mobilisation cycle and 29 (97%) within two TI cycles.
A total of 81 out of a planned 90 cycles of HDCT took place. Twenty-five (83%) patients completed three cycles of HDCT. One patient completed two cycles but had failed to harvest sufficient stem cells for a third cycle. The remaining four patients completed one cycle of HDCT only. The first of these patients refused further HDCT as he had developed worsening sensori-neural hearing loss and received a further two cycles of TI. The other three patients had developed severe neutropenic sepsis. Stem cell collectionand infusion-related data are shown in Table 1b .
In terms of toxicity, three patients were admitted to ICU with sepsis. The lengths of stay for the three ICU admissions were 27, 6 and 4 days, respectively. One patient was admitted to ICU on day +4 and died on day +10. Febrile neutropenia was the most common adverse event occurring in 69 (85%) of 81 cycles of HDCT. Three patients developed significant subjective hearing loss requiring the use of hearing aids.
The median follow-up in all patients is 46 (9-201) months. Of the 30 patients treated, 16 (53%) achieved a CR following TI-CE. A further six (20%) achieved a CRPS, yielding a total CR rate of 73%. These 22 patients are alive and disease-free at a median follow-up of 93.5 (9-201) months. Of the remaining eight patients, one died of sepsis during the post-transplant period prior to engraftment. Seven patients progressed following TI-CE, six of whom have died from disease; one patient had refractory disease and five relapsed within six months of transplant. One patient is alive with disease receiving chemotherapy, one-year post transplant.
The estimated PFS at three years is 73% (95% confidence interval (CI): 54-87%). Estimated OS at three years is 78% (95% CI: 57-89%). Twenty-five of the 30 patients have at least two years' follow-up. A total of 18 (72%) of these 25 patients are currently alive and disease-free. No significant difference in outcome based on IPFSG score was found. A treatment flow summary of all 30 patients is shown in Table 2 .
This series demonstrates the efficacy and safety of the TI-CE regimen in 30 patients with relapsed or refractory GCT treated over a 17-year period at our institution. In the most recent MSKCC update of their experience with TI-CE, there was a 5 year OS of 52%. 8 However, there were differences between our patients and those in the MSKCC cohort. Twenty-four of the 30 patients in our group were refractory or had had an IR to first-line cisplatin-based chemotherapy of whom 15 (50% of the total) had primary cisplatin-refractory disease. In contrast, of the 107 patients in the 2010 MSKCC update, 79 (74%) had primary refractory disease, 21 (20%) had mediastinal primary tumours (all non-seminomas), and seven had late relapses (42 years). Only one (3%) of our patients had a primary mediastinal GCT and there were no late relapses. Lewin et al. 10 provided further evidence of the efficacy of TI-CE in the setting of early relapse in a recent report. Their study of 17 patients treated with a number of different HDCT regimens reports a 3-year OS rate of 90% in patients who had received TI-CE at first relapse (n = 10).
The Indiana group has reported cure rates of 70% with HDCT in second-line use and 45% in those receiving treatment in the third-line setting or later. 5 The IT94 GETUG/EBMT trial is the only reported randomised trial comparing CDCT and HDCT as initial salvage for relapsed GCT. A total of 280 patients were randomised between four cycles of CDCT and three cycles of CDCT followed by one cycle of HDCT supported by autoSCT.
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There was no statistically significant difference in the outcome. Concerns have been raised about a number of aspects of this trial including the use of a single cycle of a HDCT regimen, the over-representation of low-risk patients due to the exclusion of patients with an IR to first-line therapy and a high transplantrelated mortality (9%).
Twenty-five (83%) patients completed three cycles of HDCT. In only one case was the third autoSCT not possible due to an insufficient stem cell dose. In addition, rapid cycling was achieved with a median of 21 days between all stem cell infusions. Letter to the Editor Table 2 . Letter to the Editor In summary, varying prognostic scores and a paucity of phase III data can make treatment decisions for patients with relapsed or refractory GCT difficult. The upcoming TIGER trial will compare CDCT using paclitaxel, ifosfamide and cisplatin with HDCT using the TI-CE protocol in relapsed or refractory GCTs. Pending the results of this trial, our experience provides further evidence of the feasibility and efficacy of the TI-CE regimen.
